



Detection of chromosomal abnormalities by analysis of circulating cell-free DNA

The prenatal screening test
based on a simple maternal blood sample



Ninalia NIPT at a glance

- NIPT stands for **Non-Invasive Prenatal Testing**
- Ninalia can detect if the foetus is affected by **trisomy 21, 18 or 13**

NEW

Today, this test can also screen for other chromosomal abnormalities and **chromosomal imbalances**.

- **No risk to foetus** since this test requires a simple blood draw from the mother.
- Several test options are available:
 - **Ninalia 3** (NIPT) : Trisomies 21, 18 et 13
 - **Ninalia 5** (NIPT) : Trisomies 21, 18 et 13 + fetal gender determination + sex chromosomes aneuploidies
 - **Ninalia Genomewide** (NIPT) : all autosomes + chromosomal imbalance greater than 7Mb Ninalia
 - **Genomewide Complete** (NIPT) : all autosomes + chromosomal imbalance greater than 7Mb + sex chromosomes aneuploidies + fetal gender determination

The choice of the most appropriate test based on your medical history will be discussed between you and your healthcare professional.

Advantages of Ninalia NIPT

Simple 1 Single blood sample

Safe **No risk** to foetus

Early **10** Available from week 10 of pregnancy, right after 1st trimester maternal serum markers screening


Accurate **>99.9%** Detection rate of Ninalia test,

Ninalia screening test is performed and interpreted by qualified prenatal geneticists.

Understanding the results provided by your healthcare provider



Results for trisomy 21, 18 and 13




- A positive result indicates a strong suspicion that the foetus is affected by trisomy 21, 18 or 13.
- A negative result indicates an extremely low risk but does not completely rule out the presence of the anomaly.
- Your healthcare provider, supported by Eurofins Biomnis prenatal experts, will explain the results to you and discuss the appropriate actions to take, if necessary.



Result for autosomal aneuploidies and chromosomal imbalance greater than 7 megabases

- Autosomal aneuploidies and chromosomal imbalance are rare chromosomal abnormalities. In case of positive result, your healthcare professional will explain to you the care best suited to you.

Step by step guide to Ninalia



* For example, if the sample is received in Eurofins Biomnis on a Tuesday, the results will be sent to your healthcare provider the following Monday

If you have any further questions, please ask your healthcare provider.

About Eurofins Biomnis

Eurofins Biomnis, **European leader in specialised medical pathology**, has its origins in the laboratory established by Marcel Mérieux in 1897. Its primary focus is the performance of highly specialised analyses requiring the use of **high-expertise test procedures**.

Eurofins Biomnis is active in all fields of medical pathology, in particular **foetal biochemistry and prenatal diagnostics**.

Geneticists, qualified in prenatal diagnosis and responsible for Eurofins Biomnis tests are available to prescribers to provide the best possible support in the implementation of this genetic test.

To know more about Ninalia, please visit:
www.nipt-biomnis.com

Eurofins Biomnis

International Division
 17/19 av. Tony Garnier
 BP 7322 - 69357 LYON Cedex 07 FRANCE
 E-mail: international@biomnis.eurofinseu.com

www.nipt-biomnis.com
www.eurofins-biomnis.com



Biomnis